Gibson James R II 4

What Happened
James R. Gibson II, Chief Financial Officer of Pacific Biosciences of California, Inc. (PACB), reported receipt of equity awards on 2026-02-27 totaling 1,001,544 shares. The filing shows 333,848 shares as Restricted Stock Units (RSUs) and 667,696 shares as a derivative award (option-like), both reported with an acquisition price of $0.00 (typical for compensation grants). This is an award/compensation event, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-27; Form 4 filed 2026-03-03 (timely filed).
• Awards: 333,848 RSUs (non-derivative) and 667,696 derivative units (option-based) at $0.00. Total = 1,001,544 shares.
• Vesting (footnotes):
  • RSUs: vest in equal annual installments on Feb 15 of 2027, 2028, and 2029, subject to continued service.
  • Derivative/option: vests in 36 equal monthly installments beginning March 27, 2026, subject to continued service.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Filing type: Form 4 (insider report); no sale or exercise-for-cash reported.

Context
This filing records compensation-related equity grants to the CFO. Such awards are standard executive compensation and do not reflect an immediate cash purchase or sale; they vest over time and typically aim to retain executives. Because the derivative award vests monthly and the RSUs vest annually, any future sales would depend on vesting and company policies.